French drugmaker Ipsen (Euronext: IPN) has reported growth in sales of 9.6%, reaching 654.6 million euros ($711 million) for the first quarter of 2020.
The group’s performance was driven by strong growth in its specialty care division, up 12.5% on the same period last year, with Somatuline (lanreotide), Cabometyx (cabozantinib) and Decapeptyl (triptorelin) all selling well.
On the consumer healthcare side, sales were down by 21.9%, mainly due to the negative impact of the implementation of hospital central procurement and the COVID-19 pandemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze